Last updated: 3 months ago
Neurocrine Biosciences Q4 2024 Financial Analysis: Strong Growth Amid Risks
Explore Neurocrine Biosciences' Q4 2024 report highlighting $2.4B in revenue, $341M net income, and key risks. A must-read for investors focused on biopharmaceuticals.